Compare MRBK & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRBK | IVA |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.1M | 1.1B |
| IPO Year | 2018 | 2020 |
| Metric | MRBK | IVA |
|---|---|---|
| Price | $19.85 | $4.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $20.75 | $16.20 |
| AVG Volume (30 Days) | 84.1K | ★ 681.1K |
| Earning Date | 04-23-2026 | 03-30-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ 30.34 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $6,316,000.00 | N/A |
| Revenue This Year | $25.40 | N/A |
| Revenue Next Year | $8.15 | $751.20 |
| P/E Ratio | $30.61 | ★ N/A |
| Revenue Growth | ★ 10.13 | N/A |
| 52 Week Low | $13.81 | $3.35 |
| 52 Week High | $21.59 | $7.98 |
| Indicator | MRBK | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 55.78 |
| Support Level | $19.28 | $4.11 |
| Resistance Level | $19.82 | $4.94 |
| Average True Range (ATR) | 0.48 | 0.18 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 49.59 | 68.75 |
Meridian Corp is a bank holding company based in the United States. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal and business lending and deposit services. It operates in three reportable segments, including Bank, Wealth, and Mortgage. Meridian generates maximum revenue from the Bank segment, which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans. Geographically, it operates in Pennsylvania, New Jersey, and Delaware, as well as in the Central Maryland market and southwest Florida, U.S.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.